Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International Pub Date : 2025-04-25 DOI:10.1111/bju.16751

Andrew W. Silagy, Dixon T.S. Woon, Louise Kostos, Rui Bernardino, Ting W. Yiu, Marian S. Wettstein, Hanan Goldberg, Jaime O. Herrera-Cáceres, Hina Shiakh, Gregory Nason, Alexandre Zlotta, Eleftherios Diamantis, Damien Bolton, Neil Fleshner

引用次数: 0

Abstract

To analyse whether the percentage of free to total prostate-specific antigen (%fPSA) is a prognostic biomarker in metastatic castration-resistant prostate cancer (mCRPC), as novel studies suggest an elevated %fPSA is associated with adverse oncological outcomes for men with biochemical recurrence of prostate cancer.

查看原文本刊更多论文

游离PSA占总PSA的百分比作为转移性去势抵抗性前列腺癌生存的生物标志物

分析游离前列腺特异性抗原占总前列腺特异性抗原的百分比（%fPSA）是否是转移性去势抵抗性前列腺癌（mCRPC）的预后生物标志物，因为新的研究表明，fPSA百分比升高与前列腺癌生化复发男性的不良肿瘤预后相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJU International 医学-泌尿学与肾脏学

CiteScore

9.10

自引率

4.40%

发文量

262

审稿时长

1 months

期刊介绍： BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.